LifeVantage Q1 Revenue Falls 22% to $37.1 Million as Active Accounts Drop to 98,000

SALT LAKE CITY, Utah - November 9, 2026

LifeVantage Corporation reported first-quarter fiscal 2027 revenue of $37.1 million on November 9, down 22.0 percent from $47.6 million in the quarter ended September 30, 2025, as fewer active accounts and weaker sales of its MindBody GLP-1 System outweighed contributions from the LoveBiome line it acquired in October 2025.

The Lehi, Utah-based nutrition company posted a net loss of $0.2 million, or $0.02 per diluted share, compared with net income of $2.2 million, or $0.17 per share, a year earlier. Adjusted earnings were $0.05 per share, down from $0.18. Adjusted EBITDA fell to $1.9 million, or 5.2 percent of revenue, from $3.9 million, or 8.2 percent. Foreign currency trimmed about $0.4 million, or 0.8 percentage points, from the top line.

"Despite a challenging quarter, LifeVantage has significant untapped potential, and we now have a clear strategy designed to capture it," said Terrence Moorehead, president and chief executive officer. "Our focus is on transforming LifeVantage into a more brand-driven, consumer-focused company, supported by a modern digital platform and an expanding community of consumers and brand advocates. At the same time, we are creating a more focused and efficient operating model and strengthening the underlying economics of the business. We have a lot of work to do, and building the company we envision will take time, but we have a differentiated foundation, a clear roadmap and a strong sense of urgency around execution."

Revenue in the Americas, which accounts for about 78 percent of sales, fell 22.2 percent to $29.0 million. Asia/Pacific and Europe fell 21.2 percent to $8.2 million, including a $0.4 million, or 3.9 percent, currency headwind.

Gross profit was $28.0 million, or 75.4 percent of revenue, compared with $37.8 million, or 79.5 percent, a year earlier. The company recorded a $1.045 million allowance for inventory obsolescence tied to the MindBody GLP-1 System; excluding that charge, gross margin was 78.2 percent. It also cited higher shipping and warehouse costs. Commissions and incentives were $15.4 million, or 41.4 percent of revenue, down from 43.5 percent, which LifeVantage attributed to the timing and size of promotional programs and changes in the mix of customers and independent consultants. Selling, general and administrative expense fell in dollars to $12.7 million but rose as a share of revenue to 34.3 percent from 31.2 percent. The company reported an operating loss of $0.1 million, compared with operating income of $2.3 million a year earlier; on an adjusted basis, operating income was $0.9 million.

Active accounts, the sum of consultants and customers who purchased in the prior three months, fell 19.0 percent to 98,000 from 121,000. Active independent consultants declined 16.7 percent to 40,000, and active customers declined 20.5 percent to 58,000.

LifeVantage generated $0.5 million in cash from operations in the quarter, compared with $2.3 million used a year earlier, and ended September 30 with $13.7 million in cash and cash equivalents and no debt, down from $14.9 million in cash at June 30. It did not repurchase shares during the quarter and had $58.5 million remaining under a $60 million authorization.

LifeVantage, founded in 2003 and traded on Nasdaq under the symbol LFVN, sells nutrigenomic products including the Protandim family, TrueScience Liquid Collagen, the MindBody GLP-1 System, and the LoveBiome P84 gut activator through independent consultants.